Odyssey Therapeutics (NASDAQ:ODTX) Rating Increased to Strong-Buy at HC Wainwright

HC Wainwright upgraded shares of Odyssey Therapeutics (NASDAQ:ODTX) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports.

Several other research analysts also recently weighed in on ODTX. Weiss Ratings began coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. TD Cowen assumed coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued a “buy” rating on the stock. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Cantor Fitzgerald started coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating for the company. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.75.

Odyssey Therapeutics Price Performance

Odyssey Therapeutics stock opened at $25.98 on Thursday. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $28.00. The stock has a market capitalization of $1.25 billion and a PE ratio of -3.84. The firm’s fifty day simple moving average is $19.57.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, research analysts anticipate that Odyssey Therapeutics will post -5.97 earnings per share for the current fiscal year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.